The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice

Sarah C. Forester, Joshua D. Lambert

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

(-)-Epigallocatechin-3-gallate (EGCG), has been shown to inhibit cancer in vivo. EGCG, however, is rapidly methylated by catechol-. O-methyl transferase (COMT), which reduces its cancer preventive efficacy. Tolcapone (TOL) is a clinically-used COMT inhibitor. Here, we examined the effect of TOL on the bioavailability of EGCG in male CF-1 mice. Plasma and tissue levels of EGCG and its methyl metabolites were determined following intragastric administration of EGCG (100 mg/kg), TOL (30 mg/kg), or the combination. In mice treated with EGCG, unmethylated plasma EGCG accounted for 63.4% of the total. Co-administration of TOL increased this fraction to 87.9%. In the urine, unmethylated EGCG accounted for 29.2% of the total, whereas treatment with EGCG plus TOL increased this to 81.8%. Similar effects were observed in the major organs examined. TOL effectively inhibited the methylation of EGCG in vivo. Future studies should examine the cancer preventive effects of the combination.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalJournal of Functional Foods
Volume17
DOIs
StatePublished - Aug 1 2015

Fingerprint

catechol O-methyltransferase
epigallocatechin
Biological Availability
bioavailability
mice
neoplasms
tolcapone
epigallocatechin gallate
Catechol O-Methyltransferase Inhibitors
intragastric administration
Neoplasms
catechol
Transferases
transferases
methylation
Methylation
urine

All Science Journal Classification (ASJC) codes

  • Food Science
  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

@article{6be591a8392647cba48b04bcb0df61a3,
title = "The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice",
abstract = "(-)-Epigallocatechin-3-gallate (EGCG), has been shown to inhibit cancer in vivo. EGCG, however, is rapidly methylated by catechol-. O-methyl transferase (COMT), which reduces its cancer preventive efficacy. Tolcapone (TOL) is a clinically-used COMT inhibitor. Here, we examined the effect of TOL on the bioavailability of EGCG in male CF-1 mice. Plasma and tissue levels of EGCG and its methyl metabolites were determined following intragastric administration of EGCG (100 mg/kg), TOL (30 mg/kg), or the combination. In mice treated with EGCG, unmethylated plasma EGCG accounted for 63.4{\%} of the total. Co-administration of TOL increased this fraction to 87.9{\%}. In the urine, unmethylated EGCG accounted for 29.2{\%} of the total, whereas treatment with EGCG plus TOL increased this to 81.8{\%}. Similar effects were observed in the major organs examined. TOL effectively inhibited the methylation of EGCG in vivo. Future studies should examine the cancer preventive effects of the combination.",
author = "Forester, {Sarah C.} and Lambert, {Joshua D.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.jff.2015.05.012",
language = "English (US)",
volume = "17",
pages = "183--188",
journal = "Journal of Functional Foods",
issn = "1756-4646",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice

AU - Forester, Sarah C.

AU - Lambert, Joshua D.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - (-)-Epigallocatechin-3-gallate (EGCG), has been shown to inhibit cancer in vivo. EGCG, however, is rapidly methylated by catechol-. O-methyl transferase (COMT), which reduces its cancer preventive efficacy. Tolcapone (TOL) is a clinically-used COMT inhibitor. Here, we examined the effect of TOL on the bioavailability of EGCG in male CF-1 mice. Plasma and tissue levels of EGCG and its methyl metabolites were determined following intragastric administration of EGCG (100 mg/kg), TOL (30 mg/kg), or the combination. In mice treated with EGCG, unmethylated plasma EGCG accounted for 63.4% of the total. Co-administration of TOL increased this fraction to 87.9%. In the urine, unmethylated EGCG accounted for 29.2% of the total, whereas treatment with EGCG plus TOL increased this to 81.8%. Similar effects were observed in the major organs examined. TOL effectively inhibited the methylation of EGCG in vivo. Future studies should examine the cancer preventive effects of the combination.

AB - (-)-Epigallocatechin-3-gallate (EGCG), has been shown to inhibit cancer in vivo. EGCG, however, is rapidly methylated by catechol-. O-methyl transferase (COMT), which reduces its cancer preventive efficacy. Tolcapone (TOL) is a clinically-used COMT inhibitor. Here, we examined the effect of TOL on the bioavailability of EGCG in male CF-1 mice. Plasma and tissue levels of EGCG and its methyl metabolites were determined following intragastric administration of EGCG (100 mg/kg), TOL (30 mg/kg), or the combination. In mice treated with EGCG, unmethylated plasma EGCG accounted for 63.4% of the total. Co-administration of TOL increased this fraction to 87.9%. In the urine, unmethylated EGCG accounted for 29.2% of the total, whereas treatment with EGCG plus TOL increased this to 81.8%. Similar effects were observed in the major organs examined. TOL effectively inhibited the methylation of EGCG in vivo. Future studies should examine the cancer preventive effects of the combination.

UR - http://www.scopus.com/inward/record.url?scp=84938828545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938828545&partnerID=8YFLogxK

U2 - 10.1016/j.jff.2015.05.012

DO - 10.1016/j.jff.2015.05.012

M3 - Article

C2 - 26213577

AN - SCOPUS:84938828545

VL - 17

SP - 183

EP - 188

JO - Journal of Functional Foods

JF - Journal of Functional Foods

SN - 1756-4646

ER -